Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
A 47-Year-Old With Headache, Vertigo, and Double Vision
Neurol 97:e535-e539, Frey, J.,et al, 2021
Clinicopathologic Conference, Eosinophilic Granulomatosis with Polyangiitis
NEJM 377:1569-1578, Case 32-2017, 2017
Periarteritis Nodosa
www.MedLink.com, June, Ramachandran, T. & Roos, R., 2010
Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999
Churg-Strauss Syndrome, Clinical Study and Long-Term Follow-Up of 96 Patients
Medicine 78:26-37, Guillevin,L.,et al, 1999
Small-Vessel Vasculitis
NEJM 337:1512-1523, Jennette,J.C.&Falk,R.J., 1997
Clinicopath Conf
Churg-Strauss Syndrome, Case 18-1992, NEJM 326:1204-1212992., , 1992
Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-Controlled Trial
Lancet 394:1713-1723,1687, The CRASH-3 trial collaborators, 2019
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Review of the Neurological Implications of von Hippel-Lindau Disease
JAMA Neurol 75:620-627, Dornbos, D.,et al, 2018
Human Neurexin-3a Antibodies Associate with Encephalitis and Alter Synapse Development
Neurol 86:2235-2242,2222, Gresa-Arribas, N.,et al, 2016
Treatable Neurological Disorders Misdiagnosed as Creutzfeldt-Jakob Disease
Ann Neurol 70:437-444, Chitravas, N.,et al, 2011
Neurologic Manifestations of von Hippel-Lindau Disease
JAMA 300:1334-1342, Butman,J.A.,et al, 2008
NT-3 Promotes Nerve Regeneration and Sensory Improvement in CMT1A Mouse Models and in Patients
Neurol 65:681-689, 662, Sahenk,Z.,et al, 2005
Antivonvulsants for Creutzfeldt-Jakob Disease?
Lancet 361:224, Fioel,A.,et al, 2003
Variable Presentation of Brugada Syndrome: Lessons from Three Generations with Syncope
BMJ 326:1078-1079, Plunkett,A.,et al, 2003
von Hippel-Lindau Disease
Lancet 361:2059-2067, Lonser,R.R.,et al, 2003
A Randomized Trial of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Neurol 54:603-607, Sanders,D.B.,et al, 2000
Treatment with Oral 3, 4 Diaminopyridine Improves Leg Strength in Multiple Sclerosis Patients
Neurol 47:1457-1462, Bever,C.T.,et al, 1996
Lambert-Eaton Myasthenic Syndrome Presenting with Severe Respiratory Failure
Muscle & Nerve 19:1328-1333996., Nicolle,M.W.,et al, 1996
Preliminary Trial of 3, 4-Diaminopyridine in Patients with Multiple Sclerosis
Ann Neurol 27:421-427, Bever,C.T.,et al, 1990
Atherosclerosis:Current Concepts on Pathogenesis and Interventional Therapies
Ann Neurol 26:3-12, Yatsu,F.M.&Fisher,M., 1989
3, 4-Diaminopyridine in the Treatment of Lambert-Eaton Myasthenic Syndrome
NEJM 321:1567-1571, 1607-16081989., McEvoy,K.M.,et al, 1989